Literature DB >> 16931216

Variant of adynamic bone disease in hemodialysis patients: fact or fiction?

Lillian A Rocha1, Andrea Higa, Fellype C Barreto, Luciene M dos Reis, Vanda Jorgetti, Sérgio A Draibe, Aluizio B Carvalho.   

Abstract

BACKGROUND: Adynamic bone disease is a type of renal osteodystrophy characterized by low bone turnover and paucity of bone cells. It was proposed that a new type of this disease featuring high osteoclastic resorption without parathyroid hormone stimulus and designated adynamic bone disease variant occurs in hemodialysis patients. The present study is designed to evaluate the frequency and characteristics of both diseases in a large series of bone biopsy specimens.
METHODS: We reviewed 1,160 bone biopsy specimens from hemodialysis patients. Specimens in which adynamic bone disease was diagnosed were selected and categorized as classic or variant based on osteoclastic surface.
RESULTS: In 218 bone biopsy specimens (18.8%), adynamic bone disease was identified, whereas the variant form was identified in 35 specimens (38.8%). Biopsy specimens categorized as the variant form were from patients who were younger and had greater phosphorus and parathyroid hormone levels. Histologically, the variant form presented greater osteoid volume, fibrosis volume, osteoid surface, osteoblast surface, and eroded surface. Similarly, values for all dynamic parameters were greater in the variant group. Osteoclastic surface correlated with phosphorus level, parathyroid hormone level, and osteoblast surface. Age and osteoblast surface were identified as independent determinants of the variant form.
CONCLUSION: Adynamic bone disease variant seems to occur in younger hemodialysis patients with greater levels of parathyroid hormone, which acts on cell-covered bone surfaces. It probably is a transitional phase from low- to high-turnover status, rather than a true entity within the spectrum of renal osteodystrophy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931216     DOI: 10.1053/j.ajkd.2006.05.028

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Osteoclasts: what do they do and how do they do it?

Authors:  Steven L Teitelbaum
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

2.  Can the combination of calcium and parathormone levels above K/DOQI guidelines be used as a marker of adynamic bone disease in African Americans?

Authors:  Charles J Diskin; Thomas J Stokes; Linda M Dansby; Lautrec Radcliff; Thomas B Carter
Journal:  Int Urol Nephrol       Date:  2010-06-12       Impact factor: 2.370

Review 3.  Sclerostin and CKD-MBD.

Authors:  Susan C Schiavi
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

Review 4.  Update on imaging in chronic kidney disease-mineral and bone disorder: promising role of functional imaging.

Authors:  Sharjeel Usmani; Najeeb Ahmed; Gopinath Gnanasegaran; Fahad Marafi; Tim van den Wyngaert
Journal:  Skeletal Radiol       Date:  2021-09-15       Impact factor: 2.199

5.  Adynamic bone disease-bone and beyond.

Authors:  Vincent M Brandenburg; Jürgen Floege
Journal:  NDT Plus       Date:  2008-06

Review 6.  Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches.

Authors:  Philip Düsing; Andreas Zietzer; Philip Roger Goody; Mohammed Rabiul Hosen; Christian Kurts; Georg Nickenig; Felix Jansen
Journal:  J Mol Med (Berl)       Date:  2021-01-22       Impact factor: 4.599

Review 7.  Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation.

Authors:  Jordi Bover; Mario Cozzolino
Journal:  Kidney Int Suppl (2011)       Date:  2011-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.